PHASE 2 CONFIGURATION – MODULAR PEPTIDE SYSTEMS B+D

Product Name: Phase 2 Configuration – Modular Peptide Systems B+D Configuration Classification: Extension Framework Configuration Product Information:

• Configuration Type: Elevated-Concentration Comparative Framework
• Included Modules: B, D
• Total Modules: 2
• System Compatibility: Topical System Framework
• Testing Methodology: HPLC-UV-MS
• Analytical Verification: ISO/IEC 17025 Accredited Laboratory
• Evaluation Format: Standalone Configuration or Sequential Configuration Framework

Analytical Composition: Module B

• Total Peptide Content: 0.23%
• Palmitoyl Tripeptide-38
• Palmitoyl Tetrapeptide-7
• Gel Matrix

Module D

• Total Peptide Content: 0.10%
• AHK-Cu
• Tocopherol (Vitamin E)
• Copper-Coordinated Peptide Complex
• Serum-Emulsion Matrix

Configuration Character

• Two chemistry classes
• Two delivery matrices
• Two elevated-concentration peptide compositions

Product Description: Phase 2 is one of three configurations within PHP’s Modular Peptide System, a modular framework of peptide formulations designed for research evaluation. Configurations represent defined combinations of individual modules (A through E) assembled to provide broader comparative frameworks than standalone module evaluation. Phase 2 combines two elevated-concentration, single-peptide-dominant compositions representing distinct chemistry classes within the modular framework: the concentrated palmitoylated peptide gel (Module B) and the copper-coordinated peptide complex (Module D). Together, these modules establish a focused framework integrating elevated peptide concentration, distinct formulation architectures, and separate chemistry classes. Each included module is independently verified through ISO/IEC 17025-accredited analytical testing using HPLC-UV-MS methodology. Batch-specific Certificates of Analysis are available through the COA-Topicals library. Research Framework:

• Depth-extension framework within the Modular Peptide System
• Two elevated-concentration peptide compositions
• Two distinct chemistry classes
• Two separate delivery matrices
• Focused comparative architecture

Phase 2 may be evaluated independently as a depth-extension framework or sequentially alongside Phase 1 within a structured evaluation protocol. When configurations are sequenced within a 24-hour evaluation cycle, defined separation intervals (typically ~12 hours) between configurations allow the analytical contributions of each to be observed without compositional overlap. Configuration Characteristics:

• Combines the system’s targeted module (B) with its advanced module (D)
• Incorporates both free peptide and copper-coordinated peptide chemistry
• Includes both gel and serum-emulsion delivery systems
• Focuses on concentrated, single-peptide-dominant compositions
• Provides a narrower but deeper comparative framework than Phase 1
• Introduces formulation variables not present within the foundational configuration

Position Within The System: Within the Modular Peptide System framework, Phase 2 functions as the extension configuration. Whereas Phase 1 emphasizes peptide-class diversity and compositional breadth, Phase 2 focuses on elevated-concentration architectures and chemistry-class differentiation. Together, the two modules establish a concentrated comparative framework built around distinct formulation and peptide characteristics. The configuration is designed to complement rather than replace Phase 1. Each configuration introduces different compositional variables within the overall modular framework, allowing broader comparative evaluation across concentration, chemistry class, and delivery matrix. Configuration Specifications:

• Included Modules: B + D
• Total Peptide-Dominant Compositions: 2
• Chemistry Classes: 2
• Delivery Matrices: 2
• Primary Peptides: Palmitoyl Tripeptide-38, AHK-Cu
• Supporting Component: Tocopherol (Vitamin E)
• Verification: ISO/IEC 17025 HPLC-UV-MS
• Packaging: Opaque Airless UV-Protective Packaging

Analytical Verification: Each module within Phase 2 is independently verified through ISO/IEC 17025-accredited analytical testing utilizing HPLC-UV-MS methodology. Batch-specific Certificates of Analysis are available through the COA-Topicals library. All included formulations are housed in opaque, airless, light-protective packaging designed to support compositional integrity throughout storage and evaluation. Compliance Notice: Phase 2 Configuration is FOR RESEARCH USE ONLY — NOT FOR HUMAN OR VETERINARY USE. This product is not a drug, cosmetic, food, or dietary supplement and has not been evaluated or approved by the U.S. Food and Drug Administration. It is intended solely for lawful in vitro research and not for any human or animal use. By purchasing this product, buyer represents and warrants that it will be used exclusively for lawful in vitro research in compliance with all applicable laws and regulations, and assumes all responsibility for any use inconsistent with this notice.

Product Usage: Not for Human or Veterinary Use

Pure Health Peptides products are supplied to qualified research professionals and institutional users for in vitro laboratory research only. KYC verification is required prior to order fulfillment, and we reserve the right to refuse orders that do not meet buyer qualification criteria. These products are not drugs, foods, cosmetics, diagnostic products, or dietary supplements, have not been evaluated by the FDA, and are not intended for human or animal use. Any such use is prohibited and may violate federal, state, or local law. By purchasing, the buyer represents and warrants that the product will be used solely for in vitro research. The buyer agrees to indemnify, defend, and hold harmless Pure Health Peptides, its officers, employees, and agents from and against any and all claims, damages, losses, liabilities, costs, and expenses (including reasonable attorneys fees) arising out of or relating to the buyer’s use, handling, storage, or disposition of the product in any manner inconsistent with its research-use-only designation or applicable law.